<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403247</url>
  </required_header>
  <id_info>
    <org_study_id>04T-536</org_study_id>
    <nct_id>NCT00403247</nct_id>
  </id_info>
  <brief_title>Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia</brief_title>
  <official_title>Double-Blind Vitamin Intervention to Lower Blood Homocysteine Levels: Amino Acid and Clinical Responses in Individuals With Schizophrenia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nathan Kline Institute for Psychiatric Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nathan Kline Institute for Psychiatric Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether individuals with schizophrenia who will
      take a high dose of the B-vitamins folate, B12 and pyridoxine, may experience improvement in
      their symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with schizophrenia often experience disturbing residual symptoms, even with the
      best available current treatments. Homocysteine, normally found in the body, can interfere
      with NMDA-glutamate receptor function, and this might be responsible for some of the symptoms
      of schizophrenia. This double-blind protocol will have study participants who suffer from
      schizophrenia take either a high-dose combination of folate, B12 and pyridoxine (a
      combination that can lower homocysteine in the body) or placebo for three months. Clinical
      measures (e.g., PANSS, CGI) will be taken to determine whether those taking the vitamin
      combination experience clinical benefit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood homocysteine levels</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI (Clinical Global Improvement)</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDSS (Calgary Depression Scale for Schizophrenia)</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WAIS-II Memory Scale (Immediate and Delayed)</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WAIS Digit Symbol-Coding</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wisconsin Card Sorting Test</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WAIS-II Letter-Number Sequencing Subtest</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vitamin capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Capsule with folate, Vitamin B12 &amp; pyridoxine</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsule</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Schizophrenia or Schizoaffective Disorder

          -  Ages 18-65, male or female

          -  Treatment regimen includes a new-generation antipsychotic (clozapine,
             olanzapine,risperidone, quetiapine, ziprasidone or aripiprazole)

          -  Stable medication for 4 weeks prior to screening visit

        Exclusion Criteria:

          -  Diagnosis of active substance use disorder within the last month

          -  Already taking vitamin supplements totaling &gt; 400 mcg folic acid per day, or regular
             B12 injections

          -  Pregnant or breastfeeding

          -  Seizure disorder

          -  Non-English speaking

          -  Without capacity to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William M Greenberg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Nathan Kline Institute for Psychiatric Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Nathan Kline Institute for Psychiatric Research</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2006</study_first_submitted>
  <study_first_submitted_qc>November 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2006</study_first_posted>
  <last_update_submitted>August 21, 2007</last_update_submitted>
  <last_update_submitted_qc>August 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2007</last_update_posted>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <keyword>Homocysteine</keyword>
  <keyword>Vitamins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

